Top Markets
Coin of the day
Hemostemix Inc. Hemostemix Inc.

Hemostemix Inc.

HEM
Rank in Stocks #32153
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Share Price
$0.05504527
Last synced: 2026-08-17
Market Cap
$10.89M
Change (1 day)
15.38%
Change (1 year)
-10.64%
Country
CA
Trade Hemostemix Inc. (HEM)

Category

Earnings for Hemostemix Inc. (HEM)
Earnings in 2026 TTM: 0
According to Hemostemix Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Hemostemix Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR